@GraceGregory_ tweeted, "It's official... I am jumping out of a plane to raise money for Alzheimer's Research UK! https://justgiving.com/fundraising/gracegregory As a Research Assistant at the ARUK Oxford Drug Discovery Institute, I see exactly how vital fundraising is used in developing new drugs for Alzheimer's Disease. That's why I am taking part in the ARUK skydive as part of Alzheimer's Awareness Month on the 26th September 2021. My goal is £400. If you would like to support Alzheimer's Research UK and help me reach my target, please go to my ARUK JustGiving page." (link above)
Good luck Grace!
The John Black Senior Research Fellowship aims to build on the strengths of the University's Central Nervous System (CNS) research programmes and world leading research into the discovery and translation of novel therapeutic approaches for neurodegenerative diseases, with a particular focus on Parkinson's disease. As a principal investigator, Dr Milosevic will provide strategic and academic leadership, pioneering studies and development of ...
On Friday, 5th July, Alzheimer’s Research UK President, the Rt Hon David Cameron, visited the Oxford Drug Discovery Institute. This was a great opportunity for Mr Cameron to meet the ODDI team and hear first-hand about their drug discovery research. A number of senior representatives from the University of Oxford also came along to discuss the wider neuroscience agenda in Oxford. Mr Cameron really enjoyed the visit and went away feeling ...
This week saw the University of Oxford’s Old Road Campus play host to the Mighty Quiz and raffle, in support of Alzheimer’s Research UK. Quizzers from various groups and posts came together to battle it out for the title of Mightiest Quizzers, and to raise money for dementia research and awareness. Once teams had tackled the first task – choosing an award-winning name – they went head to head, answering general knowledge questions on a variety ...
External Link found on http://aruk-oddi.medsci.ox.ac.uk/latest-news
FORMA Therapeutics and the University of Oxford Announce Multi-Year Collaboration to Advance the Development of Deubiquitinating Enzyme (DUB) Inhibitors for the Treatment of Neurodegenerative Diseases
Oxford, U.K. and Watertown, Massachusetts, USA – May 9th, 2018 – FORMA Therapeutics and the University of Oxford announced today they have entered into a collaboration and license agreement to identify, validate and develop deubiquitinating enzyme (DUB) inhibitors for the treatment of neurodegenerative diseases..
Researchers in London have identified a promising approach for tackling the hallmark Alzheimer’s disease protein, tau. The findings of the research, which was funded by Alzheimer’s Research UK, are published today (Monday 7 May) in the scientific publication Acta Neuropathologica Communications.
The research team are now working with experts from the Alzheimer’s Research UK Oxford Drug Discovery Institute to further assess the potential of targeting TAOKs to treat diseases like Alzheimer’s, and to develop this work towards something that could help people with dementia.
Alzheimer’s Research UK Oxford Drug Discovery Institute has teamed up with the University of Manchester and the Phenomics Discovery Initiative to identify small molecule inhibitors of NLRP3 inflammasome.
Oxford Drug Discovery Institute Chemist Stephen Wren will be running the London Marathon April 2019, in support of Alzheimer’s Research UK! Please click the link above to support him.